Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391091 · ClinicalTrials.gov registry record · Phase 3
Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine
A Phase 3 study of Atrial Fibrillation and Migraine, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 1
- Study location
NCT01391091 is a Phase 3 study of Atrial Fibrillation and Migraine that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 173 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01391091, a Phase 3 study of Atrial Fibrillation and Migraine, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective study is to evaluate the effect of catheter ablation on incidence, prevalence and disease-severity of migraine in AF patients undergoing ablation, with or without a history of migraine.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency catheter ablation
Study Locations (1)
Texas
- St. David's Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391091
The ClinicalTrials.gov registry entry for NCT01391091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The listed sponsor is Texas Cardiac Arrhythmia Research Foundation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency catheter ablation is the first listed.
NCT01391091 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01391091 about?
NCT01391091 is a clinical study titled "Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine". The purpose of this prospective study is to evaluate the effect of catheter ablation on incidence, prevalence and disease-severity of migraine in AF patients undergoing ablation, with or without a history of migraine.
What is the current status of trial NCT01391091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2010-12. Estimated completion is 2014-04.
What conditions does trial NCT01391091 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Migraine.
What interventions are being tested in trial NCT01391091?
The interventions under investigation include: Radiofrequency catheter ablation (PROCEDURE).
Who is sponsoring clinical trial NCT01391091?
This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01391091 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.